Canakinumab and Rilonacept
Determining the interaction of Canakinumab and Rilonacept and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using rilonacept together with canakinumab is generally not recommended. These medications may have similar effects, and combining them can increase the risk of serious infections. Contact your doctor immediately if you experience fever, chills, body aches, sore throat, muscle weakness, or other flu-like symptoms during treatment with either medication. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The concomitant use of agents that block interleukin-1 has not been studied, but may result in increased risk of neutropenia and serious infections due to additive pharmacologic effects.
MANAGEMENT: Simultaneous use of agents that block interleukin-1 or its receptors is not recommended.
- "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.
- "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Canakinumab-Rilonacept Subcutaneous
- Canakinumab-Rilpivirine
- Canakinumab-Rilpivirine Hydrochloride
- Canakinumab-Rilutek
- Canakinumab-Riluzole
- Canakinumab-Riluzole Suspension
- Rilonacept-Canakinumab Subcutaneous
- Rilonacept-Canasa
- Rilonacept-Canasa Pac rectal
- Rilonacept-Canasa rectal
- Rilonacept-Cancidas
- Rilonacept-Candesartan